Participated · Series A · May 2026

Latus Bio develops a gene therapy platform that pairs proprietary and engineered AAV capsids with clinically optimized routes of administration to enable efficient delivery at low doses. The company’s two lead programs are LTS-101 for CLN2 disease, which has IND clearance and multiple FDA designations, and LTS-201 for Huntington’s disease, which is being prepared for IND submission. Latus is advancing capsid variants for potential application beyond CNS disorders, including kidney, eye, heart, and muscle diseases. Management emphasizes scalability and lower-dose delivery to improve safety, manufacturability, and cost, targeting larger rare and broader CNS indications. The company raised $97 million in its Series A (including a $43 million extension) to fund operations through key clinical milestones for these programs.

Led · Equity · Mar 2026

Founded in 2024 and based in Philadelphia, Ajaya Bio is developing bispecific antibodies that link a targeting arm for pathogenic inflammatory cells with an arm that recruits immune cells to kill those targets. Its lead program targets rheumatoid arthritis and is currently in preclinical animal studies. The company was bootstrapped by founders Mohit Sachdeva and Ramesh Singh, participated in the HiveBio accelerator, and has a four-person team. Ajaya raised $1 million from BioAdvance Capital and Ben Franklin Technology Partners to support preclinical work and plans to file an IND after manufacturing its drug. Management aims to raise a Series A to fund manufacturing, regulatory filings, a clinical trial, and team expansion, and also intends to develop a broader pipeline for other autoimmune and potentially cancer indications.

Participated · Seed · Oct 2024

Tolerance Bio is developing a pipeline of therapies that target thymus biology to preserve, restore and modulate thymic function with the goal of re-establishing immune tolerance. Its pipeline modalities include monoclonal antibodies, cell therapies, and mRNA approaches. The company is advancing a celiac disease program that aims to retrain immune responses by targeting the thymus and is pursuing preclinical proof-of-concept work. Tolerance Bio positions its platform as potentially applicable beyond celiac disease to a broader set of autoimmune conditions. The company announced a strategic investment from Beyond Celiac Investments to support early development and accelerate its path to the clinic. No revenue, user, or other operating metrics were disclosed in the articles.

Participated · Series A · Jul 2023

KayoThera is developing first-in-class, oral small-molecule inhibitors that target the retinoid pathway. The platform originated from biology discovered at Princeton University by Mark Esposito and Yibin Kang. The company is advancing lead programs in diabetes and oncology, including therapies for late-stage and metastatic cancers. KayoThera states the additional resources will support IND-enabling safety studies and position programs for strategic partnering. To date the company has secured $14 million in total financial support, comprised of equity and non-dilutive grant funding. Recent grants include NIH SBIR awards (NIDDK and NCI) and funding from the Andy Hill Cancer Research Endowment (CARE) Fund. KayoThera is an early-stage therapeutics company developing a new class of cancer immunotherapies grounded in research from Princeton University. The company was co-founded in 2019 by Mark Esposito and Yibin Kang and has identified a family of key enzymes targetable with novel small molecule inhibitors. KayoThera is advancing a lead oncology program aimed at treating late-stage and metastatic cancers, including breast, lung, pancreatic, colorectal, brain, and kidney cancers. The firm plans to move its lead program toward the clinic to translate its discoveries into therapies for patients with advanced disease. Leadership includes Dr. Esposito as Vice President of Research and Development and Dr. Kang as Chair of the Scientific Advisory Board. Financially, KayoThera received initial backing from Foundation Venture Capital Group and has recently closed a Series A to fund development.

Participated · Series D · Jan 2023

Palvella Therapeutics focuses on developing and commercializing novel therapies for serious, rare genetic skin diseases that currently lack FDA-approved treatments. The company advances a broad pipeline built on its patented QTORIN platform, initially targeting lifelong rare skin disorders. Palvella works with patient advocacy organizations and patient registries to design accelerated development programs to expedite patient access to targeted therapies. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel, being developed for pachyonychia congenita, microcystic lymphatic malformations, and prevention of basal cell carcinomas in Gorlin syndrome. QTORIN rapamycin has received FDA Fast Track Designation for all three indications. The company recently completed a Series D financing to support advancement of QTORIN rapamycin across these indications. Palvella Therapeutics is a Wayne, PA–based rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments. Its lead program, PTX-022 (QTORIN™ 3.9% rapamycin anhydrous gel), is in a Phase 2/3 pivotal study for pachyonychia congenita (PC), a rare, chronically debilitating and lifelong genetic disease estimated to affect more than 9,000 individuals in the U.S. The company partners with patient advocacy organizations and patient registries to design fit-for-purpose, accelerated clinical development programs aimed at expediting targeted therapies to patients lacking approved options. Palvella intends to use the proceeds from the financing to advance PTX-022 in adults with PC. Wes Kaupinen serves as President and CEO. In conjunction with the funding, Scott Morenstein of CAM Capital and Cory Freedland of Samsara BioCapital joined Palvella’s Board of Directors. Palvella Therapeutics is a Wayne, PA-based rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for debilitating, rare genetic diseases with no approved treatments. The company is led by Wes Kaupinen, president and chief executive officer. Its lead program, PTX-022 (QTORIN™ rapamycin formulation), is entering Phase 2/3 development for pachyonychia congenita (PC). PC is a rare, chronically debilitating lifelong monogenic disease in which mutations in keratin genes lead to dysregulated keratinocyte proliferation, increased skin fragility and impaired plantar skin barrier function. Palvella will continue to retain responsibility for all clinical development, regulatory, manufacturing, marketing and other commercialization activities worldwide. The company has secured external development funding to advance PTX-022.